Navigation Links
BioMed Realty Trust Announces Public Offering Price for 22,562,922 Shares of Common Stock
Date:11/14/2011

SAN DIEGO, Calif., Nov. 14, 2011 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that the public offering price for the 22,562,922 shares of its common stock previously sold to UBS Investment Bank, the sole underwriter for the offering, is $17.92 per share, for expected gross proceeds of approximately $404.3 million, before underwriting discounts and estimated expenses.

UBS Investment Bank served as the sole underwriter for the offering.  

The registration statement relating to these securities became effective upon filing with the Securities and Exchange Commission.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed's common stock, nor shall there be any sale of such common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement and the accompanying prospectus may be obtained from:UBS Investment BankProspectus Department299 Park AvenueNew York, NY 10171or by telephone toll free at 888-827-7275About BioMed Realty TrustBioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in properties comprising approximately 12.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, Maryland, San Diego, New York/New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research.  

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; reductions in asset valuations and related impairment charges; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston University Biomedical Engineers Find Chink in Bacterias Armor
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. Voler Systems President Speaks at BIOMEDevice San Jose
11. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/27/2017)... , ... June 27, 2017 , ... Hammer Strength, the ... (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning ... award is decided by NBSCA members who vote to select the coach who embodies ...
(Date:6/27/2017)... ... June 27, 2017 , ... East Los Angeles dentist, Ramin ... about early life experiences. What happens to a woman during pregnancy can have profound ... can also take a toll on a baby’s long-term health. This study, which was ...
(Date:6/26/2017)... ... ... Dental Center is now offering various types of dental implants to restore lost teeth. ... prosthetic teeth, such as crowns, bridges, or dentures. An implant is placed directly into the ... for the tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... Maryland’s soybean farmers have improved ... released by the United Soybean Board. , Thanks to the responsible use ... their productivity on less land per bushel, the report says. The United Soybean ...
(Date:6/26/2017)... ... June 26, 2017 , ... If ... are seeing lots of red these days. According to recent estimates, 75 – ... from medical coding errors(1). Some studies point to Electronic Health Records (EHR) with ...
Breaking Medicine News(10 mins):